View TAVR Unload information

The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate aortic stenosis (AS) compared with optimized heart failure therapy (OHFT).

Primary Investigator: Michael Salinger, MD
Subinvestigator: Peter Mason, MD; Paul Pearson, MD; Josh Meskin, MD; Fasseas Panayotis, MD; Dhiraj Baruah, MD; Nunzio Gaglianello, MD; David Ishizawar, MD; Zachary Laste, MD

Status: Currently enrolling
Sub Category: Heart Valve Disease

View Early TAVR information

To establish the safety and effectiveness of the Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, California) Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis

Primary Investigator: Peter Mason, MD
Subinvestigator: Michael Salinger, MD; Paul Pearson, MD; Joshua Meskin, MD; Panayotis Fasseas, MD; Dhiraj Baruah, MD; James Kleczka, MD; Zachary Laste, MD

Status: Currently enrolling
Sub Category: Heart Valve Disease

View REPRISE IV information

This is a prospective, multicenter single-arm study designed to evaluate the safety and effectiveness of the LOTUS Edge Valve System for TAVR in symptomatic subjects who have severe native aortic stenosis and are considered at intermediate risk for surgical valve replacement.

Primary Investigator: Michael Salinger, MD
Subinvestigators: Peter Mason, MD; Paul Pearson, MD; Joshua Meskin, MD; 

Status: Currently enrolling
Sub Category: Heart Valve Disease